FDA Approval Alert: The Need-to-Know | Sotorasib/Panitumumab in KRAS G12C-Mutated Colorectal Cancer

In January 2025, the FDA approved sotorasib plus panitumumab for patients with KRAS G12C-mutated metastatic colorectal cancer, determined by an FDA-approved test, and for those who have previously received therapy including fluoropyrimidine, oxaliplatin, or irinotecan.